CAIRO — Egypt’s Nile Company for Pharmaceuticals and Chemical Industries reported a sharp increase in profitability during the first nine months of the current fiscal year, reflecting strong operational performance and revenue expansion, according to an official disclosure to the Egyptian Exchange.
The company said net profits rose by 92% year-on-year to approximately EGP 239.06 million for the period from July 2025 to March 2026, compared with EGP 124.65 million recorded in the corresponding period a year earlier, as cited by Mubasher.
Revenue growth significantly outpaced earnings, nearly doubling to EGP 1.91 billion during the nine-month period, up from EGP 968.23 million in the previous fiscal year. The performance underscores improving demand dynamics within Egypt’s pharmaceutical sector, alongside enhanced production and distribution efficiency.
The earnings expansion comes amid broader resilience in Egypt’s healthcare and pharmaceuticals industry, which has increasingly benefited from sustained domestic demand and strategic positioning in regional export markets.
As The Middle East Observer notes, the company’s strong financial trajectory highlights the sector’s capacity to deliver growth despite macroeconomic pressures, reinforcing pharmaceuticals as a defensive and increasingly attractive segment within Egypt’s equity landscape.
